1. Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
- Author
-
K. Abraham Peele, Shraddha Parate, Vikas Kumar, T.C. Venkateswarulu, Krupanidhi Srirama, and Keun Woo Lee
- Subjects
Pharmaceutical Science ,02 engineering and technology ,Molecular Dynamics Simulation ,Pharmacology ,medicine.disease_cause ,Antiviral Agents ,030226 pharmacology & pharmacy ,Molecular Docking Simulation ,Docking ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,medicine ,Humans ,Repurposing ,Coronavirus ,Virtual screening ,SARS-CoV-2 ,Molecular dynamics simulations ,Chemistry ,Drug Repositioning ,COVID-19 ,Membrane Proteins ,021001 nanoscience & nanotechnology ,Drug repositioning ,MM-PBSA ,Pharmaceutical Preparations ,Membrane protein ,Docking (molecular) ,0210 nano-technology ,Rapid Communication - Abstract
The novel coronavirus (SARS-CoV-2) outbreak has started taking away the millions of lives worldwide. Identification of known and approved drugs against novel coronavirus disease (COVID-19) seems to be an urgent need for the repurposing of the existing drugs. So, here we examined a safe strategy of using approved drugs of SuperDRUG2 database against modeled membrane protein (M-protein) of SARS-CoV-2 which is essential for virus assembly by using molecular docking-based virtual screening. A total of 3639 drugs from SuperDRUG2 database and additionally 14 potential drugs reported against COVID-19 proteins were selected. Molecular docking analyses revealed that nine drugs can bind the active site of M-protein with desirable molecular interactions. We therefore applied molecular dynamics simulations and binding free energy calculation using MM-PBSA to analyze the stability of the compounds. The complexes of M-protein with the selected drugs were simulated for 50 ns and ranked according to their binding free energies. The binding mode of the drugs with M-protein was analyzed and it was observed that Colchicine, Remdesivir, Bafilomycin A1 from COVID-19 suggested drugs and Temozolomide from SuperDRUG2 database displayed desirable molecular interactions and higher binding affinity towards M-protein. Interestingly, Colchicine was found as the top most binder among tested drugs against M-protein. We therefore additionally identified four Colchicine derivatives which can bind efficiently with M-protein and have better pharmacokinetic properties. We recommend that these drugs can be tested further through in vitro studies against SARS-CoV-2 M-protein.
- Published
- 2021
- Full Text
- View/download PDF